

Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110 020 (INDIA)
T: +91-11- 33550700, 47317000
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 03rd February 2025

Scrip Code: - 531768

The Manager,
BSE Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.

Scrip Code:- POLYMED

The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block-G
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.

Sub: Submission of Press Release for the Unaudited Financial Results(Standalone & Consolidated) for Third Quarter and Nine Months ended on December 31, 2024

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release with respect to Unaudited Financial Results(Standalone & Consolidated) for Third Quarter and Nine Months ended on December 31, 2024.

Request you to take the same on records.

Thanking You,

Yours Sincerely

For Poly Medicure Limited

Avinash Chandra
Company Secretary
M. No. A32270



Poly Medicare Limited Reports Third-Quarter FY 2025 Results

Quarterly and Nine Months Consolidated Revenue growth of 25% and 23% respectively on a YoY basis

Quarterly and Nine Months Consolidated EBITDA growth of 28% on a YoY basis, Q3 Core EBITDA margin 27.4%

Consolidated Quarterly and PAT Growth of 31% and 30% respectively on a YoY basis; Q3 PAT margin of 20.1%

New Delhi, February 3rd, 2025: Poly Medicare Ltd. (NSE: POLYMED | BSE: 531768), India's leading Medical Device company with a dominant position in medical consumables market, today announced its unaudited consolidated and standalone financial results for the quarter and nine months ended on December 31st, 2024.

Key Financial Summary:

Consolidated Rs. Crores	Q3 2025	Q3 2024	YoY Growth (%)	YTD December 2025	YTD December 2024	YoY Growth (%)
Consolidated Revenue from Operations	424.2	339.6	24.9%	1229.0	997.7	23.2%
EBITDA	116.3	90.9	27.9%	336.7	263.9	27.6%
<i>EBITDA Margin</i>	27.4%	26.8%	+63BPS	27.4%	26.5%	+95BPS
Profit after Tax	85.2	65.0	31.1%	246.7	189.9	29.9%
<i>Profit after Tax Margin</i>	20.1%	19.1%	+95BPS	20.1%	19.0%	+104BPS
EPS - Basic	8.5	6.8	25.3%	25.2	19.8	27.4%

Key Financial Highlights:

- Revenue from operations increased by 25% in Q3 2025 compared to Q3 2024, underscoring our robust market presence and effective growth strategies; nine months revenue growth stood at 23%.
- Export revenue for the nine months increased by 29% YoY, driven by continued strong performance in key international markets.
- The domestic quarterly and nine month revenue growth of 24% and 17% YoY respectively on a YoY basis, demonstrating our continued investments in building R&D and sales capabilities.
- Renal division continues to gain market share in the domestic market with revenue growth of 50% and 56% in Q3 and 9 month period respectively.
- EBITDA grew by 28% in Q3 2025 compared to Q3 2024, reflecting our strong earnings capability from core operations. The EBITDA margins improved by 63BPS to 27.4% in Q3 2025.
- Profit After Tax (PAT) increased by 31% in Q3 2025 compared to Q3 2024, demonstrating our commitment to delivering shareholder value. The PAT margin expanded by almost 100BPS to 20% in Q3 2025.
- The balance sheet position continues to be strong with Net Cash of Rs. 1074crs as on December 31, 2024; well capitalised to capture growth opportunities in the sector.

Commenting on the results for the quarter, Mr. Himanshu Baid, Managing Director, Poly Medicare Limited stated:

We are extremely pleased with our continued growth in the business in the last quarter. Overall revenue grew by almost 25% with EBITDA and PAT growing by 28% and 31% respectively. We are on track to achieve our revenue growth guidance of 22-24% while improving our EBITDA margin by 100 – 150BPS.

I am very excited to share that we have received regulatory approval to launch our Drug Eluting Stent and commercialisation of that is expected soon. That will give an significant fillip to our Cardiology business. We continue to invest aggressively in building our manufacturing capacities and recently ground-breaking ceremony was held at our Palwal Plant, which will be the largest plant that we would be setting up at a single location. We have also signed a JV agreement to set up a 10MW Solar Power plant in Haryana where we will own 26% stake. This will go a long way in achieving our sustainability goals and reduce our carbon-footprint.

We are very excited about the growth opportunity that India provides in the MedTech sector and our continued investments strongly reflects in that belief.

About Poly Medicare Limited:

Poly Medicare Ltd is a leading medical device manufacturer and exporter from India, with its products sold in over 125 countries, making a significant global impact on healthcare. With a robust portfolio of over 200 medical devices and more than 300 patents, Polymed offers a comprehensive range of medical devices across 12 medical therapies, including infusion therapy, vascular access, dialysis and renal care, critical care, cardiology, oncology, transfusion, diagnostics, gastroenterology, anaesthesia and respiratory care, urology, and surgery and wound management. Supported by 12 state-of-the-art manufacturing facilities across 4 countries, Polymed has the capacity to produce over 1.5 billion medical devices annually, meeting the ever-growing global demand. The company's diverse product offering ensures it addresses a wide range of medical needs worldwide.

Disclaimer:

This press release contains forward-looking statements based on current expectations, assumptions, estimates, and projections about Poly Medicare Limited and its industry. These forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to differ materially include, but are not limited to, changes in economic conditions, competitive landscape, regulatory developments, and other risks detailed in the company's filings with regulatory authorities. Poly Medicare Limited undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

The financial information provided in this press release is unaudited and subject to change. Investors are advised to review the company's audited financial statements and other disclosures available on the company's website and through regulatory filings.

For more details, please contact:

Rahul Gautam

Investor Relations
rahul.gautam@polymedicure.com

Hitesh Sardana,

Corporate Communication
hitesh.sardana@polymedicure.com